Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 12/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 4/20 | 0.43 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30583494 | 1.00 | ESR1 (0.45) | ESR1ESR2ELANEAPPPCSK9 | |
| SCHEMBL21814880 | 0.81 | ELANE (0.47) | ESR1ESR2ELANEAPP | |
| SCHEMBL24095251 | 0.80 | ESR1 (0.49) | ESR1ESR2APP | |
| SCHEMBL24095229 | 0.80 | FBP1 (0.50) | ELANEAPPPCSK9 | |
| SCHEMBL21814848 | 0.79 | ESR1 (0.47) | ESR1ESR2APP | |
| SCHEMBL5021496 | 0.78 | PCSK9 (0.59) | ELANEPCSK9 | |
| SCHEMBL26265051 | 0.78 | ELANE (0.49) | ESR1ESR2ELANEAPP | |
| SCHEMBL21815371 | 0.77 | ESR1 (0.43) | ESR1ESR2APP | |
| SCHEMBL21815006 | 0.77 | APP (0.46) | ESR1ESR2APP | |
| SCHEMBL24095302 | 0.76 | ESR1 (0.42) | ESR1ESR2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787791-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787791-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2023-09-21 | — | — | US | disclosed |
| US-20210387975-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2021-12-16 | — | — | US | disclosed |
| CN-113164454-A | Inhibitors of VAP-1 | 奥克塞拉有限公司 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787791-B2 | Inhibitors of VAP-1 | VAPB, VAPA, TOE1 | ESR1 4245/4885ESR2 3315/4885ELANE 1288/4885 |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | VAPB, VAPA, TOE1 | ESR1 4245/4885ESR2 3315/4885ELANE 1288/4885 |
| US-20210387975-A1 | INHIBITORS OF VAP-1 | VAPB, VAPA, TOE1 | ESR1 4245/4885ESR2 3315/4885ELANE 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.